SS-31, known in clinical development as elamipretide (and historically as MTP-131 and Bendavia), is a synthetic aromatic-cationic tetrapeptide from the Szeto-Schiller family of mitochondria-targeted compounds. The SS peptides emerged from research into small peptides that concentrate in mitochondria without depending on the organelle's membrane potential — a property that distinguishes them from most mitochondria-targeted small molecules, which accumulate electrophoretically and lose targeting as membrane potential collapses in dysfunctional mitochondria. That distinction is exactly what made SS-31 interesting to mitochondrial researchers: it reaches the compartment it is studied in even when that compartment is failing.
Structurally, SS-31 is built from alternating aromatic and basic residues — a design motif of the SS series in which the aromatic rings and cationic charges cooperate to drive both membrane penetration and selective binding to anionic mitochondrial lipids. Researchers should reference the batch Certificate of Analysis for the confirmed sequence, salt form, and molecular weight of any specific research lot. The peptide is studied almost entirely for one reason: its selective, reversible binding to cardiolipin, the signature phospholipid of the inner mitochondrial membrane.
What is cardiolipin, and why does binding it matter?
Cardiolipin is a structurally unusual phospholipid — four acyl chains rather than two, with a compact double-glycerophosphate head group — found almost exclusively in the inner mitochondrial membrane, where it can constitute a substantial fraction of the lipid content. It is not a passive structural component. Cardiolipin stabilizes the cristae folds that give the inner membrane its surface area, anchors the respiratory chain complexes, promotes their assembly into supercomplexes, and holds cytochrome c at the membrane surface. When cardiolipin is oxidized or lost, published research associates the change with cristae disruption, less efficient electron transfer, increased electron leak, and progression toward apoptotic signaling.
This is what makes a selective cardiolipin-binding peptide a valuable research tool. Published biophysical work characterizes SS-31 as binding cardiolipin-containing membranes and interacting with the cardiolipin-cytochrome c relationship in ways studied for their effect on the peroxidase chemistry that oxidizes cardiolipin's acyl chains. In cell-based and preclinical models, SS-31 treatment has been examined for preservation of cristae architecture, maintenance of respiratory complex function — including Complex I and Complex IV activity readouts — and reduction of lipid-peroxidation markers under oxidative challenge. The framing across this literature is consistent: SS-31 is used to probe whether protecting the inner membrane's lipid environment preserves the bioenergetic machinery embedded in it.
How is SS-31 studied in electron transport chain research?
The electron transport chain converts reducing equivalents into the proton gradient that powers ATP synthesis, and its efficiency depends on the physical organization of its complexes within the cardiolipin-rich inner membrane. Research using SS-31 in mitochondrial preparations and cell models typically measures oxygen consumption rates, ATP output, membrane potential, and reactive oxygen species production under stress conditions — ischemia-reperfusion models, chemical uncoupling, hyperglycemic challenge, and aging-associated dysfunction among them.
Published studies in aged animal models have reported that SS-31 treatment was associated with improved skeletal-muscle mitochondrial energetics in vivo, which is one reason the peptide became a fixture of the geroscience literature: it offered a pharmacological test of the hypothesis that age-related bioenergetic decline is partly a membrane-lipid problem rather than purely a matter of accumulated genomic damage. That hypothesis remains under active investigation, and SS-31 remains one of the standard tools for probing it in laboratory models.
What happened with elamipretide as a drug program?
SS-31's clinical-development history is unusually long and instructive. Under the name elamipretide, the compound was taken through trials in several indications over more than a decade — including cardiovascular and mitochondrial-disease programs with mixed primary-endpoint results — before the program narrowed to Barth syndrome, a rare X-linked genetic disorder in which mutations in the tafazzin gene impair cardiolipin remodeling. Barth syndrome is, mechanistically, the purest possible match for a cardiolipin-targeted peptide: the disease is defined by abnormal cardiolipin.
In September 2025, the FDA granted accelerated approval to elamipretide under the brand name Forzinity for improving muscle strength in Barth syndrome patients meeting a weight threshold — the first approved therapy for the condition. For the research community, the approval matters as a proof point about the biology: a regulatory endorsement, under the accelerated-approval framework, that targeting cardiolipin is a viable mechanistic strategy in at least one defined disease context. It should be read no more broadly than that. The approval covers a specific pharmaceutical product in a specific rare-disease population; it says nothing about any other use of the peptide, and research-grade SS-31 is a laboratory reagent, not a pharmaceutical. Ever Vital makes no therapeutic claims for SS-31 or any research compound.
How does SS-31 relate to MOTS-c in the mitochondrial research axis?
The mitochondrial axis now dominates the cellular-aging literature, and its two most-published peptides approach the organelle from opposite directions. MOTS-c is a mitochondrial-derived signal — a peptide encoded within the mitochondrial genome that communicates metabolic state outward to the cell, studied for AMPK pathway activation and nuclear translocation under stress (covered in depth in our MOTS-c research overview). SS-31 is a mitochondrial-targeted effector — a synthetic peptide delivered inward to the organelle, studied for stabilizing the membrane environment in which respiration happens.
Recent literature has begun examining mechanism-paired designs that use both peptides in the same experimental program: one arm probing signaling and metabolic flexibility, the other probing structural preservation of the respiratory machinery. For laboratories studying cellular aging, the pairing is attractive precisely because the mechanisms are complementary rather than overlapping — a functional-plus-structural read on the same organelle. The same logic connects SS-31 research to the broader redox network Ever Vital's catalog serves: lipid peroxidation in the inner membrane consumes the cell's reducing capacity, linking cardiolipin protection studies to glutathione pathway research and to the NAD-dependent enzymology covered in our NAD+ overview.
How is SS-31 studied in cellular aging models?
Aging research uses SS-31 across several model layers. In cell culture, senescence and oxidative-stress models measure whether cardiolipin protection shifts viability, ROS accumulation, and mitochondrial morphology readouts. In aged-animal studies, published work has examined muscle energetics, cardiac function parameters, kidney and retinal models, and exercise-capacity measures, with results that vary by tissue, model, and protocol — a heterogeneity that is itself informative, suggesting the peptide's studied effects depend on how central cardiolipin damage is to a given tissue's aging phenotype. Reviews of the SS-peptide literature consistently identify the strongest and most reproducible signals in models where oxidative membrane damage is the primary lesion.
For researchers designing studies, the practical takeaways from the published record are straightforward: SS-31's studied activity is membrane-localized and stress-dependent, baseline effects in healthy preparations are typically modest, and assay designs that include an oxidative or bioenergetic challenge are where the literature has found its clearest contrasts.
What should researchers know before working with SS-31?
SS-31 is supplied as a lyophilized powder for laboratory research use only and is not intended for human use. As with any research peptide, sequence identity and purity should be confirmed against the batch Certificate of Analysis, and the peptide's stability characteristics make standard cold-chain and desiccated storage practices appropriate for maintaining research-grade material. Its clinical namesake's approval has raised the compound's profile sharply — searches and community discussion around "SS-31" and "elamipretide" have grown accordingly — but the research-use compound and the approved pharmaceutical occupy entirely separate regulatory categories, and conflating them is both scientifically sloppy and legally wrong. What the approval genuinely offers researchers is narrower and more valuable: independent validation that the cardiolipin mechanism SS-31 was designed around is real enough to build on.
Cited literature
References
Primary literature and public databases referenced above. Each link resolves on the publisher or database of record.
